Medical marketers are ready to move away from AI as a buzzword while sports marketing opportunities emerge at Digital Pharma ...

In 2004, the National Hockey League lockout went into effect ... In 2021, Health Canada announced new names for the Pfizer-BioNTech, Moderna and Oxford-AstraZeneca COVID-19 vaccines based on a request ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

Per an article by Seeking Alpha (“SA”), AstraZeneca AZN dismissed a media report that claimed it may shift its vaccine manufacturing site from the U.K. to the United States. This reported ...

A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates. The results from the trial showed that the ...

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...

Five AstraZeneca staff have been detained in China amid claims of potential illegal activity at the British drug giant. Authorities in Shenzhen, China, are investigating how the company collected ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

AstraZeneca, Wang added, aims to become an multinational company that combines innovation from both China and the West, according to a post on AstraZeneca’s official WeChat account. (Updates ...

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor.